ESR1 and triple-negative breast carcinoma: Interestingly, combined treatment with 5-aza and trichostatin A (an inhibitor of histone deacetylase) could epigenetically activate ER in triple-negative breast cancer cells (MDA-MB-231), thus making them sensitive to tamoxifen [81].